Elfabrio is a drug used for long-term enzyme replacement therapy in adult patients with an established diagnosis of Fabry disease.
This medicine contains the active substance pegunigalsidase-alfa. Pegunigalsidase-alpha is a covalent conjugate of prh-alpha-GAL-A with polyethylene glycol (PEG).
Elfabrio is available as a 2 mg/ml concentrate for solution for infusion.
